New IV Medication for Psoriatic Arthritis

The US Food and Drug Administration has approved an intravenous (IV) formulation of secukinumab (Cosentyx) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non–radiographic axial spondyloarthritis (nr-axSpA). 

Secukinumab is the only treatment approved in an IV formulation that specifically targets and blocks interleukin-17A and the only non–tumor necrosis factor alpha IV option available to treat the three indications of PsA, AS, and nr-axSpA, according to the drug’s manufacturer, Novartis.

The approval marks the first new IV treatment in six years for these three conditions. The drug was first approved in 2015 and up to now has been available only as a subcutaneous injection.  Some patients are not comfortable with self-injections or favor having treatments administered in their healthcare provider’s office.  Also, the approval of Cosentyx as an IV formulation expands the treatment options available with a different mechanism of action than existing biologic IV therapies, combined with the comfort and familiarity of an established treatment.

The new formulation is also approved for secukinumab’s other indications of plaque psoriasis in people aged 6 years or older, children aged 2 years or older with PsA, and enthesitis-related arthritis in patients aged 4 years or older.

This IV formulation is administered monthly in a 30-minute, weight-based dosing regimen.